Table 1.
Baseline characteristics by C-reactive protein group among all 9270 SHARP participants
| Baseline characteristic | C-reactive protein (mg/l) |
||
|---|---|---|---|
| <3 (n = 4298) | ≥3 (n = 4305) | Not available (n = 667) | |
| CRP (mg/l) (median, IQR) | 1.2 (0.7–2.0) | 7.1 (4.6–13.5) | - |
| Age at randomization (yrs) | 61 (12) | 63 (12) | 62 (12) |
| Men | 2630 (61%) | 2773 (64%) | 397 (60%) |
| Prior vascular disease | 576 (13%) | 733 (17%) | 84 (13%) |
| Diabetes | 917 (21%) | 1034 (24%) | 143 (21%) |
| Current smoker | 532 (12%) | 615 (14%) | 87 (13%) |
| Diastolic blood pressure (mm Hg) | 80 (12) | 78 (13) | 78 (13) |
| Systolic blood pressure (mm Hg) | 139 (21) | 139 (23) | 140 (22) |
| LDL cholesterol (mmol/l) | 2.82 (0.89) | 2.74 (0.86) | 2.70 (0.85) |
| HDL cholesterol (mmol/l) | 1.17 (0.35) | 1.06 (0.32) | 1.10 (0.26) |
| Apolipoprotein A1 (mg/dl) | 139 (29) | 128 (28) | 136 (30) |
| Apolipoprotein B (mg/dl) | 96 (26) | 97 (25) | 94 (25) |
| Albumin (g/l) | 40.7 (3.6) | 39.5 (3.7) | - |
| Body mass index (kg/m2) | 25.8 (4.5) | 28.3 (6.1) | 27.3 (6.0) |
| Ethnicity | |||
| White | 2944 (68%) | 3258 (76%) | 444 (67%) |
| Black | 88 (2%) | 120 (3%) | 56 (8%) |
| Asian | 1150 (27%) | 803 (19%) | 133 (20%) |
| Other/not specified | 116 (3%) | 124 (3%) | 34 (5%) |
| Co-medication | |||
| Antiplatelet therapy | 852 (20%) | 1112 (26%) | 141 (21%) |
| ACE inhibitor or ARB | 2447 (57%) | 2263 (53%) | 320 (48%) |
| Beta blocker | 1620 (38%) | 1657 (38%) | 237 (36%) |
| Calcium channel blocker | 1891 (44%) | 1694 (39%) | 255 (38%) |
| Renal status | |||
| Not on dialysis | 3188 (74%) | 2631 (61%) | 426 (64%) |
| On dialysis | 1110 (26%) | 1674 (39%) | 241 (36%) |
| MDRD-estimated GFR (ml/min per 1.73m2)a,b | |||
| Mean (SD) | 26.9 (13.7) | 26.2 (12.2) | 25.4 (12.4) |
| ≥60 | 61 (2%) | 26 (1%) | 1 (0%) |
| ≥30 to <60 | 1159 (36%) | 924 (35%) | 72 (34%) |
| ≥15 to <30 | 1315 (41%) | 1162 (44%) | 88 (42%) |
| <15 | 652 (20%) | 518 (20%) | 49 (23%) |
| Not available | 1 | 1 | 216 |
| Urinary albumin:creatinine ratio (mg/g)a,b | |||
| Median (IQR) | 206 (50–725) | 206 (51–645) | 206 (206–206) |
| <30 | 584 (20%) | 481 (20%) | 42 (22%) |
| ≥30 to ≤300 | 1120 (38%) | 925 (39%) | 63 (32%) |
| >300 | 1280 (43%) | 987 (41%) | 90 (46%) |
| Not available | 204 | 238 | 231 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease Study.
Data are n (%), mean (SD), or median (IQR).
a
Among patients not on dialysis.
b
Percentages exclude participants for whom data were not available for that category.